

FOUNDATION

# Ahetract

	Abstract		Federated	Set of HD Tools	s Authored b	by the Commu	nity	
	gton's Disease in High Definition; HDinHD.org) is an al designed for Huntington's Disease (HD) researchers	CHDI	HD Explorer	Integrated network of H community omics repo			zed from the literatu	re,
[1]. HDinHD pres	sents a synthesized view of HD experimental data and rated set of visualization and analysis tools developed	GeM-HD Consortium	GeM Euro 9K	Visualization tools and genetic modifiers of Hu			sociation study to ide	ntify
by HD scient	ists. Researchers can interactively explore an	CHDI	ASViewer	Visualization of Q-leng brain and peripheral tis			n expression data from	m
download datase	et of experimental data, visualize analytical results or ets to incorporate into their own local databases and	Khakh Lab (UCLA)	Adult Astrocyte RNAseq Explorer	Visualization tool provi HD disease models.	ding Astrocyte gen	e expression profiles	across brain regions	and
	am continues to monitor the literature and community	Neri Lab (INSERM)	Brain-C lab HD Knowledge base	Browsable knowledget learning and 3D-visual				
studies are curated and analyzed according to established vocabularies,		Ma'ayan Lab (Mt. Sinai)	Enricher	Gene set enrichment analysis tool operating over a large, diverse collection of generation including HDSigDB, a gene set library containing HD and HD-related generation of generation and HD-related generation.			e set e sets.	
methods and pip HDinHD seeks to and may be subr	belines and integrated into the HDinHD environment. b be responsive to community needs. Input is welcomed mitted either through the Feedback link on the HDinHD ntacting CHDI directly.	Yang Lab (UCLA)	<b>CoExMap Viewer</b>	Visualization tool allow Weighted Gene Co-ex intact mouse striatum a transcriptomic signatur knockout mice and wild	ving exploration of r pression Network A at 6-months of age res of differentially	results and underlying Analysis (WGCNA) of as well as from gene	g data of a large-scal f hundreds of sample e set enrichment anal	le es from lysis of
	Downloads			Tools: H	<b>ID</b> Explorer			
Striatum Disease Signature Mouse Allelic	Manuscript describing generation of molecular disease signatures in HD mice and supplemental files detailing results [2]. Raw, processed and analyzed molecular and behavioural	HD and HD- Experimenta	related al Data Curated	n=2,166 PubMed	n=20 bioRxiv; Research Square	n=77 (325) CRO Reports Commissioned by C		Omics
Series GWAS Studies	data from the Mouse Allelic Series project. Topic reports for genes implicated by early GeM-HD results.	& Analyzed and Externa	from Internal Sources.			rovenance		
DNA Repair & Handling	Topic reports for genes implicated by early Generic Dresults. Topic report plus visual and computable DNA repair pathways.	Shared HD (	Catalogs allow	Perturbation n=11,80	<b>68</b>	n=14,638	Iolecular Studies n=964	
Causal Modeling Results	Simulation and other results from a series of causal models built from Mouse Allelic Series molecular and behavioural data.	Models, Trea	ng on Mouse atments and			ative HD Catalogs		
Curated HD Datasets	Independent slices of HD experimental data, including HDSigDB, that underlie HD Explorer.	Genes/Targo	ets.	HD Mouse M n=193	H	turbations of ID Models n=9,906	Genes of Interest Genome-wide	
	HDSigDB Gene Sets			HD Explore	er Entry Port	als		
we developed a core of <b>HDSigD</b> triplet-repeat e ArrayExpress, a selected PubMe Response pathw In Summer 2023 introduce a new sets" are constru	unctional context for HD gene set enrichment analysis, n HD-relevant gene set library called <b>HDSigDB</b> . The <b>B</b> is derived from curation and analysis of HD and xpansion disease studies deposited in GEO, nd PRIDE. Additional sources of gene sets include ed articles (publication-based) and DNA Damage ays (CHDI reports). 3, we leveraged large-scale HD perturbation data to type of gene set within <b>HDSigDB</b> . "Perturbation gene etced by grouping a set of perturbed genes that share a aggregation – and result – e.g. the treatment effect		d experimental data de experimental data de experimental data de Public CHD CHD CHD	Ans and reports linked to escribed within HDinHD. ations and Reports Perturbation Studies Reset Ink to a diverse ene-specific al data within HD hd to federated applications.	Results of perturbations studies performed in the HD context described in publications and CHDI reports.         HDSigDB is a	users can pivot v links to explore re tools or adjace sections. After e users can check of gene/protein in t and visit sets of performed on th	al gene name sear ortals into the inte- olication. Inside a ria a rich set of se elated HDinHD fee ent HD Explore on the expression he Mouse Allelic of experimental	rch box egrated portal, emantic derated r data name, of that Series studies

Outcomes are now presented

at the arm-level for >4,250

pages

key experimental data from

these studies, including arm-

level metadata and genotype

effects and phenotype effects

and

for

chemically-induced

summarizing

include

studies drawn from

now

publications

download files

for all outcomes.

Drilldown

studies

effects,

e.g. me neament effect e.g. aggregation and result IEauuui (perturbed HD vs HD) shows amelioration or exacerbation of a phenotype as compared to the genotype effect (HD vs WT).


Gene Set Source	# of Gene Sets
CHDI report-based	38
Dataset analysis-based	3,350
Perturbation-based	465
Publication-based	1,238

To provide further granularity and interpretability, we broke down each group independently by 2 experimental factors related to the HD Model:

Does the experiment utilize an **in vitro**, **in vivo** or **ex vivo** HD model? Does the HD Model contain a **fragment** or **full-length** mHTT construct?

Each perturbation gene set has a direct link to each perturbation experiment contributing to the perturbation gene set.

Source Gene Set Perturbations										
Z	Summary	Gene Symbol	Model Category	mHTT Length	Perturbation	Perturbation Type				
0	Activation of a heat shock response by geldanamycin inhibits aggregation caused by expression of Htt exon 1 with 72 glutamines (HD72Q) in COS-1 cells.	HSP90AA1, HSP90AB1	in vitro	exon 1	geldanamycin	inhibitor, inhibitor				
0	Hsp40 overexpression decreased the amount of insoluble aggregates caused by expression of Htt exon 1 with 51 glutamines (HD51Q) by 30-40% in COS-1 cells.	HSPA1A	in vitro	exon 1	pTL1-HA3-Hsp70	overexpression				
0	Simultaneous co-expression of Hsp40 and Hsp70 decreased the amount of insoluble aggregates caused by expression of Htt exon 1 with 51	DNAJB1, HSPA1A	in vitro	exon 1	pTL10-FLAG-Hdj-1, pTL1-HA3-Hsp70	overexpression				



>600

these

PDF

reports.

Library designed to provide rich functional context for HD-related gene set enrichment analysis. Gene sets have been derived from publications, CHDI internal reports and community omics repositories.

context.

Component datasets are available for downloads to support labs who wish to incorporate batch data from HD Explorer as part of internal databases and analytical pipelines.

# **Perturbation Studies**

#### Summary of Findings

0564-0000-002 treatment on 1) motor deficits, 2) survival, 3) whole brain, at 10 and 12 weeks of age. Within females treated with 1 and 10 mg/kg of CHDI-00200564-0000-002 had decreased grip strength at 4 weeks of age baseline. Within females the mice treated with

						Exp	erimental Arn	าร			
	Cohort	Arm	Strain	Perturbation			Agent Dose	Number of Anima	Is Route of Administration	Perturbation Regimen	Perturbation Time
	Main cohort	1	wild type	10% hydroxypropyl-beta-cyclodextrin in 50 mM citrate buffer (pH 5.5) 0			0 mg/kg	9 (M):10 (F)	oral gavage	once a day	from 4 to 25 wk
/	Main cohort	2	R6/2	10% hydroxypropyl-beta-cyclodextrin in 50 mM citrate buffer (pH 5.5) 0			0 mg/kg	11 (M):10 (F)	oral gavage	once a day	from 4 to 25 wk
	Main cohort	3	R6/2	CHDI-00200564			1 mg/kg	9 (M):9 (F)	oral gavage	once a day	from 4 to 25 wk
	Main cohort	4	R6/2	CHDI-00200564			3 mg/kg	9 (M):10 (F)	oral gavage	once a day	from 4 to 25 wk
	Main cohort	5	R6/2	CHDI-00200564			10 mg/kg	9 (M):10 (F)	oral gavage	once a day	from 4 to 25 wk
						0	utcome Data				
Arm	n 🖹 Ct Ar	rl m	Contrast Type	■ Outcome Type	<b>≧</b> Tissue	<b>≣</b> Assay	■ Readout Measurement	nt Pooled Outco		■ Female Outcome	Phenotype Direction
2	1		genotype effect	imaging	brain	magnetic resonance in	naging region volum	decrea	se decrease	decrease	
2	1		genotype effect	imaging	cerebral cortex	magnetic resonance in	naging region volur	ne decrea	se decrease	decrease	
2	1		genotype effect	imaging	corpus striatum	magnetic resonance in	naging region volum	ne decrea	se decrease	decrease	

### **Omics Studies**

Over 474 HD and HD-related (most often, neurodegenerative repeat-expansion diseases) studies identified largely from within public omics repositories have been curated using controlled vocabularies and ontologies to standardize metadata. The studies were divided into >960 datasets based on platform, tissue, etc. The bulk of these datasets were analyzed independently using a consistent and standard methodology. Full

glutamines (HD51Q) by 60-80% in COS-1 cells. Analysis by indirect immunofluorescence microscopy revealed that neither the overexpression of HSP40 nor that of Hsp70 was able to prevent the accumulation of large perinuclear inclusions with aggregated HD51Q protein. In contrast, when both chaperones were co-expressed with HD51Q the large perinuclear inclusion bodies totally disappeared.

**HDSigDB** is available within HDinHD Downloads as lists of human and mouse gene symbols and Entrez gene IDs. It is also integrated within HD Explorer. **HDSigDB** is also included in the Enricher, a gene set enrichment analysis package from Ma'ayan Lab (Mt. Sinai) (https://maayanlab.cloud/Enrichr/) [3-5].

differential gene expression results are now available for direct download for 650 core platform datasets.

Platform	# of Studies			RNAseq data on HDAC Class IIa inhibitor (CHDI-00390576) dosed Q175 mice		
RNAseq	330			Omics Studies		
miRNAseq	26	Select Study	Project Name	Summary	Experimental Factor	Tissue
• •	20	۲	GSE104064.SS1- cerebral_cortex	Cerebral cortex tissue was collected from Huntington's (zQ175 KI) mice treated with CHDI-00390576 or a vehicle and wild-type mice (n=8 per condition). Tissue was examined by RNA sequencing.	Perturbation Group	cerebral cortex
ATACseq	2	0	GSE104064.SS2- corpus_striatum	Corpus striatum tissue was collected from Huntington's (zQ175 KI) mice treated with CHDI-00390576 or a vehicle and wild-type mice (n=8 per condition). Tissue was examined by RNA sequencing.	Perturbation Group	corpus striatum
microarray	263	0	GSE104064.SS3-tibialis	Tibialis striatum tissue was collected from Huntington's (zQ175 KI) mice treated with CHDI-00390576 or a vehicle and wild-type mice (n=8 per condition). Tissue was examined by RNA sequencing	Perturbation Group	tibialis
proteomics	29	Get Resu	p-value and FDR-adj	ression analysis was run on all Contrasts within this study and results are presented in an Excel-compatible CSV file. Results columns typical justed p-value (for genes which pass the DESeq2 filter threshold) for each Contrast. Both significant and insignificant results are included. Sta mes are provided for each row.		

# Acknowledgements

HDinHD is funded and developed by CHDI Foundation, Inc., a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of those affected by Huntington's disease. HDinHD was launched in 2015 in partnership with the laboratory of Giovanni Coppola (UCLA). Colleagues at Rancho BioSciences contributed data curation, data analysis, data modeling and software/data engineering support, and Bridlewood Consulting contributed solutions architecture, systems and software engineering support. CHDI thanks the investigators who have kindly contributed to HDinHD's federated set of community-developed tools.

	References		■%[
<ol> <li>Aaronson J et al, J Huntington's Dis 2021,10(3):405-412.</li> <li>Obenauer J et al, bioRxiv, <u>https://doi.org/10.1101/2022.02.04.479180</u>.</li> </ol>	3. Chen EY et al, <i>BMC Bioinformatics</i> 2013, 128(14). 4. Kuleshov MV et al, <i>Nucleic Acids Research</i> 2016, gkw377.	4. Xie Z et al, <i>Current Protocols</i> 2021, doi:10.1002/cpz1.90. 5. Wang N et al, <i>Neuron</i> 2022, 110(20):3318-3338.	